Search

XL765

It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

Tozorakimab

Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. … moderate-to-severe asthma), NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in

Tirilazad

Tirilazad has been used in trials studying the treatment of Spinal Cord Injury.

2,3-Dimercapto-1-propanesulfonic acid

t-Butylhydroquinone

Eritoran

Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

Alferminogene tadenovec

Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease

Aloe vera flower

Aloe vera flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Corydalis ambigua tuber

Corydalis ambigua tuber is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Lonicera caprifolium flower

Lonicera caprifolium flower is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.